Pharma Stocks, Sun Pharma, Cadila, Cipla
Divis Laboratories, maker of active pharmaceutical ingredients (APIs) and drug intermediates, will spend Rs 15 billion to expand existing facilities over the next 15 months.
The company said it would be investing Rs 6 billion each on its Unit-2 at the Vizag SEZ in Andhra and Unit-1 of its Nalgonda SEZ in Telangana. And, another Rs 3 billion for de-bottlenecking at Vizag. All the work is expected to be complete by end-December 2019. The company currently operates four multipurpose manufacturing facilities, from these two sites.
The management said the investment was to cater for the rising opportunities in generic and
First Published: Oct 30 2018 | 5:30 AM IST